Skip to main content

Advertisement

SpringerLink
Log in

SABR vs. Limited Resection for Non-small Cell Lung Cancer: Are We Closer to an Answer?

  • Lung Cancer (HA Wakelee, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Lobectomy is currently the guideline-recognized gold standard for the treatment of early-stage non-small cell lung cancer (ES-NSCLC) in patients who are surgical candidates. In patients who are not medically fit for surgery, stereotactic ablative radiotherapy (SABR) is the treatment of choice with good reported rates of local control and overall survival. For patients at high risk for lobectomy, sublobar resection (SLR) may achieve similar outcomes as lobectomy, especially for peripheral tumors ≤2 cm. While there are merits to both SLR and SABR for these high-risk patients, evidence is conflicting on which may be preferred in the context of clinical and cost-effectiveness outcomes. For SABR, a histologic diagnosis is preferred prior to treatment. However, some individuals may be at high risk for biopsy, and a likelihood-of-malignancy probability threshold of >85 % has been proposed as reasonable to proceed with SABR in a positron emission tomography (PET)-positive lesion without histology. Increased risks of SABR are noted in ultra-central tumors and in patients recently treated with anti-VEGF therapy. Co-existing interstitial lung disease can cause increased treatment-related toxicity in both SABR and surgery. Toxicity is generally well tolerated for SABR and SLR, though treatment-related mortality may be higher in surgery. Ongoing comparative effectiveness research, especially through randomized control trials, is crucial in further delineating the roles of SLR and SABR in the treatment of ES-NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

    Article  CAS  PubMed  Google Scholar 

  2. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology—non-small cell lung cancer National Comprehensive Cancer Network 2015 [version 6.2015]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

  3. Vansteenkiste J, Crino L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, et al. 2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014;25(8):1462–74.

    Article  CAS  PubMed  Google Scholar 

  4. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S–313S.

    Article  CAS  PubMed  Google Scholar 

  5. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60(3):615–22. discussion 22-3.

    Article  CAS  PubMed  Google Scholar 

  6. Qiao X, Tullgren O, Lax I, Sirzen F, Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003;41(1):1–11.

    Article  PubMed  Google Scholar 

  7. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81(5):1352–8.

    Article  PubMed  Google Scholar 

  8. Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):348–53.

    Article  PubMed  Google Scholar 

  9. Timmerman RD, Paulus R, Pass HI, Gore E, Edelman MJ, Galvin JM, et al. RTOG 0618: stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients. J Clin Oncol. 2013;31(15 Suppl):7523.

    Google Scholar 

  10. Mery CM, Pappas AN, Bueno R, Colson YL, Linden P, Sugarbaker DJ, et al. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest. 2005;128(1):237–45.

    Article  PubMed  Google Scholar 

  11. Wisnivesky JP, Henschke CI, Swanson S, Yankelevitz DF, Zulueta J, Marcus S, et al. Limited resection for the treatment of patients with stage IA lung cancer. Ann Surg. 2010;251(3):550–4.

    Article  PubMed  Google Scholar 

  12. Fan J, Wang L, Jiang GN, Gao W. Sublobectomy versus lobectomy for stage I non-small-cell lung cancer, a meta-analysis of published studies. Ann Surg Oncol. 2012;19(2):661–8. This meta-analysis of mostly retrospective studies from 1990 to 2010 showed that OS and CSS were superior for lobectomy compared to SLR. In subgroup analyses, there was no difference in OS or CSS between lobectomy and SLR for ES-NSCLC ≤2 cm. When only segmentectomy was considered, there was no difference in OS or CSS between lobectomy and segmentectomy.

    Article  PubMed  Google Scholar 

  13. Khullar OV, Liu Y, Gillespie T, Higgins KA, Ramalingam S, Lipscomb J, et al. Survival after sublobar resection versus lobectomy for clinical stage IA lung cancer: an analysis from the national cancer data base. J Thorac Oncol. 2015;10(11):1625–33. In contrast, this population-level PS-matched analysis showed that OS was lower for either wedge resection or segmentectomy when compared individually to lobectomy. Lymph node upstaging was also significantly lower with segmentectomy or wedge resection compared to lobectomy. Wedge resection was associated with a higher likelihood of inadequate margin status. There was no difference in 30-day mortality between these treatment modalities.

    Article  PubMed  Google Scholar 

  14. Speicher PJ, Gu L, Gulack BC, Wang X, D’Amico TA, Hartwig MG, et al. Sublobar resection for clinical stage IA non-small-cell lung cancer in the United States. Clin Lung Cancer. 2016;17(1):47–55.

    Article  PubMed  Google Scholar 

  15. Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg. 2006;132(4):769–75.

    Article  PubMed  Google Scholar 

  16. Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, Hillman SL, Heron DE, et al. Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer. J Clin Oncol. 2014;32(23):2456–62.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Cao C, Chandrakumar D, Gupta S, Yan TD, Tian DH. Could less be more?-a systematic review and meta-analysis of sublobar resections versus lobectomy for non-small cell lung cancer according to patient selection. Lung Cancer. 2015;89(2):121–32. This meta-analysis introduced the idea of “intentional” versus “compromised” SLR. For intentional SLR, patients who could have tolerated a lobectomy received SLR due to small tumor size, peripheral tumor location, adequate margin status, or presence of ground glass opacity on CT. SLR was compromised when the patient was at high surgical risk for lobectomy. There was no difference in OS between lobectomy and intentional SLR, but OS was superior for lobectomy compared to compromised SLR.

    Article  PubMed  Google Scholar 

  18. Fernando HC, Landreneau RJ, Mandrekar SJ, Hillman SL, Nichols FC, Meyers B, et al. Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III study. J Thorac Cardiovasc Surg. 2011;142(5):1143–51.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. 2015.

  20. Gazala S, Pelletier JS, Storie D, Johnson JA, Kutsogiannis DJ, Bedard EL. A systematic review and meta-analysis to assess patient-reported outcomes after lung cancer surgery. Scientific World Journal. 2013;2013:789625.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Poghosyan H, Sheldon LK, Leveille SG, Cooley ME. Health-related quality of life after surgical treatment in patients with non-small cell lung cancer: a systematic review. Lung Cancer. 2013;81(1):11–26.

    Article  PubMed  Google Scholar 

  22. Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, DiPetrillo TA, Meyers BF, et al. Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: results from the ACOSOG Z4032 (Alliance) multicenter randomized trial. J Thorac Cardiovasc Surg. 2015;149(3):718–25. discussion 25-6.

    Article  PubMed  Google Scholar 

  23. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Timmerman RD, Hu C, Michalski J, Straube W, Galvin J, Johnstone D, et al. Long-term results of RTOG 0236: a phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;90(1).

  25. Videtic GM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR, et al. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2015;93(4):757–64.

    Article  PubMed  Google Scholar 

  26. Zheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2014;90(3):603–11.

    Article  PubMed  Google Scholar 

  27. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–7. This pooled analysis of data from the ROSEL and STARS RCTs showed that SABR achieved superior 3-year OS compared to lobectomy. However, the sample size was still relatively small with 58 patients.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010;28(6):928–35.

    Article  PubMed  Google Scholar 

  29. Matsuo Y, Chen F, Hamaji M, Kawaguchi A, Ueki N, Nagata Y, et al. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: a propensity score matching analysis. Eur J Cancer. 2014;50(17):2932–8.

    Article  PubMed  Google Scholar 

  30. Shirvani SM, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, et al. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg. 2014;149(12):1244–53. This population-level PS-matched study using the SEER database from 2003 to 2009 showed that SLR was associated with a lower OS and CSS compared to lobectomy. OS was similar for SABR and lobectomy for PS-matched patients.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Ezer N, Veluswamy RR, Mhango G, Rosenzweig KE, Powell CA, Wisnivesky JP. Outcomes after stereotactic body radiotherapy versus limited resection in older patients with early-stage lung cancer. J Thorac Oncol. 2015;10(8):1201–6. In contrast, this population-level PS-matched study using the SEER database from 2002 to 2009 showed no differences in OS between SABR and SLR. However, when SLR was stratified into segmentectomy and wedge resection, there were no differences in OS between SABR and wedge resection but segmentectomy was associated with a better OS compared to SABR.

    Article  PubMed  Google Scholar 

  32. Verstegen NE, Oosterhuis JW, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A, et al. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol. 2013;24(6):1543–8.

    Article  CAS  PubMed  Google Scholar 

  33. Rusthoven CG, Kavanagh BD, Karam SD. Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data. Ann Transl Med. 2015;3(11):149.

    PubMed  PubMed Central  Google Scholar 

  34. Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol. 2010;95(1):32–40.

    Article  CAS  PubMed  Google Scholar 

  35. Chen H, Louie AV, Boldt RG, Rodrigues GB, Palma DA, Senan S. et al. Quality of life after stereotactic ablative radiotherapy for early-stage lung cancer: a systematic review. Clin Lung Cancer. 2015.

  36. Louie AV, van Werkhoven E, Chen H, Smit EF, Paul MA, Widder J, et al. Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: results from the ROSEL multicenter randomized trial. Radiother Oncol. 2015;117(1):44–8.

    Article  PubMed  Google Scholar 

  37. Nguyen TK, Goodman CD, Boldt RG, Warner A, Palma DA, Rodrigues GB et al. Evaluation of health economics in radiation oncology: a systematic review. Int J Radiat Oncol Biol Phys. 2015.

  38. Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon Jr RM, Blum D, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009;27(23):3868–74.

    Article  PubMed  Google Scholar 

  39. Louie AV, Rodrigues GB, Palma DA, Senan S. Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada. Oncologist. 2014;19(8):880–5.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Smith BD, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, et al. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. J Geriatr Oncol. 2015;6(4):324–31.

    Article  PubMed  Google Scholar 

  41. Louie AV, Senan S, Patel P, Ferket BS, Lagerwaard FJ, Rodrigues GB, et al. When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer?: a decision analysis. Chest. 2014;146(4):1021–8.

    Article  PubMed  Google Scholar 

  42. van den Berg LL, Klinkenberg TJ, Groen HJ, Widder J. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC. J Thorac Oncol. 2015;10(5):826–31.

    Article  PubMed  Google Scholar 

  43. Verstegen NE, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol. 2011;101(2):250–4.

    Article  PubMed  Google Scholar 

  44. Kelly K, Altorki NK, Eberhardt WE, O’Brien ME, Spigel DR, Crino L, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol. 2015;33(34):4007–14.

    Article  CAS  PubMed  Google Scholar 

  45. Kent M, Landreneau R, Mandrekar S, Hillman S, Nichols F, Jones D, et al. Segmentectomy versus wedge resection for non-small cell lung cancer in high-risk operable patients. Ann Thorac Surg. 2013;96(5):1747–54. discussion 54-5.

    Article  PubMed  Google Scholar 

  46. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–9.

    Article  PubMed  Google Scholar 

  47. Felip E, Rosell R, Maestre JA, Rodriguez-Paniagua JM, Moran T, Astudillo J, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28(19):3138–45.

    Article  CAS  PubMed  Google Scholar 

  48. Sun V, Kim JY, Williams AC, Raz DJ, Sampath S, Ferrell B. Quality of life and symptoms following stereotactic body radiotherapy in early-stage lung cancer patients. J Commun Support Oncol. 2014;12(11):407–14.

    Article  Google Scholar 

  49. Tagawa T, Iwata T, Nakajima T, Suzuki H, Yoshida S, Yoshino I. et al. Evolution of a lung-sparing strategy with sleeve lobectomy and induction therapy for non-small cell lung cancer: 20-year experience at a single institution. World J Surg. 2015.

  50. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–9.

    Article  PubMed  Google Scholar 

  51. Senthi S, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol. 2013;106(3):276–82. This systematic review showed that SABR can result in tolerable toxicity and good local control for centrally located ES-NSCLC if tumor BED10 ≥ 100 Gy and normal tissue BED3 ≤ 210 Gy.

    Article  PubMed  Google Scholar 

  52. Mangona VS, Aneese AM, Marina O, Hymas RV, Ionascu D, Robertson JM, et al. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis. Int J Radiat Oncol Biol Phys. 2015;91(1):124–32.

    Article  PubMed  Google Scholar 

  53. Haseltine JM, Rimner A, Gelblum DY, Modh A, Rosenzweig KE, Jackson A, et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol. 2015. This study showed that SABR was associated with a high rate of treatment-related mortality with tumors abutting the proximal bronchial tree. Treatment with bevacizumab peri-SABR occurred in both patients who died from hemoptysi.

  54. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol. 2011;6(12):2036–43.

    Article  PubMed  Google Scholar 

  55. Palma D, Lagerwaard F, Rodrigues G, Haasbeek C, Senan S. Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys. 2012;82(3):1149–56.

    Article  PubMed  Google Scholar 

  56. Inoue T, Shiomi H, Oh RJ. Stereotactic body radiotherapy for Stage I lung cancer with chronic obstructive pulmonary disease: special reference to survival and radiation-induced pneumonitis. J Radiat Res. 2015;56(4):727–34.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Takeda A, Kunieda E, Ohashi T, Aoki Y, Oku Y, Enomoto T, et al. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest. 2012;141(4):858–66.

    Article  PubMed  Google Scholar 

  58. Ishijima M, Nakayama H, Itonaga T, Tajima Y, Shiraishi S, Okubo M, et al. Patients with severe emphysema have a low risk of radiation pneumonitis following stereotactic body radiotherapy. Br J Radiol. 2015;88(1046):20140596.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Yamaguchi S, Ohguri T, Matsuki Y, Yahara K, Oki H, Imada H, et al. Radiotherapy for thoracic tumors: association between subclinical interstitial lung disease and fatal radiation pneumonitis. Int J Clin Oncol. 2015;20(1):45–52.

    Article  PubMed  Google Scholar 

  60. Bahig H, Filion E, Vu T, Roberge D, Lambert L, Bouchard M, et al. Excellent cancer outcomes following patient-adapted robotic lung SBRT but a case for caution in idiopathic pulmonary fibrosis. Technol Cancer Res Treat. 2015;14(6):667–76. This study showed that SABR could be associated with increased treatment-related toxicity in patients with coexisting ILD. Three of five patients with ILD in this study experienced grade 5 toxicity after SABR.

    PubMed  Google Scholar 

  61. Yoshitake T, Shioyama Y, Asai K, Nakamura K, Sasaki T, Ohga S, et al. Impact of interstitial changes on radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Anticancer Res. 2015;35(9):4909–13.

    PubMed  Google Scholar 

  62. Fukui M, Suzuki K, Oh S, Matsunaga T, Miyasaka Y, Kawagoe I, et al. Distribution of interstitial pneumonia: a new radiological predictor of 90-day mortality after resection of lung cancer. Surg Today. 2016;46(1):66–73.

    Article  CAS  PubMed  Google Scholar 

  63. Yano M, Yoshida J, Koike T, Kameyama K, Shimamoto A, Nishio W, et al. Survival of 1737 lobectomy-tolerable patients who underwent limited resection for cstage IA non-small-cell lung cancer. Eur J Cardiothorac Surg. 2015;47(1):135–42. This study showed that in patients who underwent SLR for ES-NSCLC, the presence of ILD (interstitial pneumonia) was associated with lower OS, DFS, and recurrence-free survival on multivariate analysis.

    Article  PubMed  Google Scholar 

  64. Voltolini L, Bongiolatti S, Luzzi L, Bargagli E, Fossi A, Ghiribelli C, et al. Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors. Eur J Cardiothorac Surg. 2013;43(1):e17–23.

    Article  PubMed  Google Scholar 

  65. Hopmans W, Zwaan L, Senan S, van der Wulp I, Damman OC, Hartemink KJ, et al. Differences between pulmonologists, thoracic surgeons and radiation oncologists in deciding on the treatment of stage I non-small cell lung cancer: a binary choice experiment. Radiother Oncol. 2015;115(3):361–6.

    Article  PubMed  Google Scholar 

  66. Charles C, Whelan T, Gafni A. What do we mean by partnership in making decisions about treatment? BMJ. 1999;319(7212):780–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, London Regional Cancer Program, Western University, Commissioners Road East, N6A 4L6, London, ON, Canada

    Hanbo Chen M.D. & Alexander V. Louie M.D., M.Sc., F.R.C.P.C.

  2. Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands

    Alexander V. Louie M.D., M.Sc., F.R.C.P.C.

Authors
  1. Hanbo Chen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander V. Louie M.D., M.Sc., F.R.C.P.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander V. Louie M.D., M.Sc., F.R.C.P.C..

Ethics declarations

Conflict of Interest

Hanbo Chen and Alexander V. Louie declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Lung Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, H., Louie, A.V. SABR vs. Limited Resection for Non-small Cell Lung Cancer: Are We Closer to an Answer?. Curr. Treat. Options in Oncol. 17, 27 (2016). https://doi.org/10.1007/s11864-016-0407-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-016-0407-3

Keywords

Search

Navigation